Institute For Molecular Medicine Inc.

Institute For Molecular Medicine Inc. is a non-profit corporate entity located in Huntington Beach, California, registered in the System for Award Management (SAM) since November 2007. The organization specializes in advanced medical research, particularly focusing on neurodegenerative disease prevention and innovative vaccine development. As a tax-exempt research institution, the entity provides scientific research services primarily through federal grant awards, with a concentrated focus on developing preventive medical interventions for complex neurological conditions.

The organization has secured multiple significant federal grant awards from the National Institute on Aging (NIA) for groundbreaking research in neurodegenerative disease prevention. These grants include a $9,781,240 project focused on a Phase 1 clinical trial for a preventive tau vaccine targeting Alzheimer's disease, a cooperative agreement for developing a vaccine for Lewy Body Dementia, and a project grant for a first-in-human DNA vaccine targeting amyloid-beta in early-stage Alzheimer's subjects. The research consistently demonstrates a strategic approach to developing immunogenic preventive vaccines, with an emphasis on early intervention strategies for neurodegenerative conditions. Each grant involves sophisticated medical research targeting specific neurological pathologies, including tau aggregates, alpha-synuclein, and amyloid-beta, with the ultimate goal of preventing or delaying cognitive decline through innovative immunotherapy approaches.